Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.
Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.
Cinctive Capital Management LP increased its stake in Hologic, Inc. (NASDAQ: HOLX) by 53.4% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,404 shares of the medical equipment provider's stock after acquiring an additional 23,119 shares during the period. Cinctive Capital Management LP's holdings
Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Hologic, Inc. (NASDAQ: HOLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,539 shares of the medical equipment provider's stock, valued at approximately $576,000. A number of other
HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.
GE HealthCare is gaining ground with strong backlog, AI-driven imaging advances and rising service capture, while Hologic's buyout caps near-term upside.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.